Athera concludes follow-up visits in multiple dosing trial with its immunovascular antibody
Stockholm Sept 19, 2017
Athera Biotechnologies AB today announced that all follow-up visits (12 weeks after last dosing) in a multiple dosing study in healthy volunteers with its fully human antibody PC-mAb have been completed. Positive preliminary safety and pharmacokinetics data provides continued support for further clinical development with once monthly administrations.
“We are very happy with the preliminary data of this study which supports our development plans and the upcoming initiation of the Phase 2a study”, says Carina Schmidt, CEO of Athera.
The fully human PC-mAb is designed to mimic the anti-inflammatory role of endogenous antibodies against PC, and act to support the immune response to vascular inflammation challenges, and thereby reduce the risk for complications.
For more information, contact: Carina Schmidt, CEO, Athera Biotechnologies AB Phone: +46 (0)76 1938 190, email: firstname.lastname@example.org
Läs mer på MyNewsDesk